Esophagus
Dupixent induces histologic remission in up to 68% of children with PPI-refractory EoE
Treatment with Dupixent led to histologic remission at week 16 among a greater percentage of pediatric patients with eosinophilic esophagitis refractory to proton-pump inhibitor therapy compared with placebo, according to study results.
GLP1-RAs linked to notably higher rate of retained gastric contents during upper endoscopy
More than 9% of patients on glucagon-like peptide-1 receptor agonists who underwent esophagogastroduodenoscopy had retained gastric contents, although the risk for aspiration remained low, according to study results.
VIDEO: Consider sleep quality, ‘next-day functioning’ in patients with nocturnal heartburn
In this Healio video, David A. Johnson, MD, MACG, FASGE, MACP, reminds physicians to ask patients with nocturnal heartburn or GERD about associated sleep disturbances, which can negatively affect “next-day functioning” and quality of life.
Device to move esophagus may make catheter ablation for AF safer
A device to move the esophagus away from the catheter tip during ablation for atrial fibrillation reduced esophageal injury during procedures, according to the results of the EASY AF study presented at Heart Rhythm 2023.
Signaling pathway ‘key needle within the haystack’ driving Barrett’s, esophageal cancer
Researchers have identified a cell signaling pathway involved in the development of Barrett’s esophagus and esophageal adenocarcinoma, which may lead to possible life-saving therapy for this aggressive cancer.
VIDEO: What’s in a name? The pathologist behind Zenker’s diverticulum
In this Endo-Sketch, a Healio video series on clinical conditions named after famous colleagues, Klaus Mergener, MD, of the University of Washington School of Medicine, discusses the origin of Zenker’s diverticulum.
ACG updates guidance for diagnosis, management of Barrett’s esophagus
The ACG issued revised clinical guidelines for the diagnosis and management of patients with Barrett’s esophagus, which were published in the American Journal of Gastroenterology.
Is FDA approval in sight for emerging EoE therapies?
Over the years, there have been many advances in the pathologic understanding of eosinophilic esophagitis, but FDA-approved treatment options have lagged.
Budesonide for EoE: Why the FDA denial is so hard to swallow
In December 2021, the FDA issued a complete response letter to Takeda Pharmaceutical Company for its new drug application for budesonide oral suspension for the treatment of eosinophilic esophagitis in adolescents and adults.
Novel risk model predicts treatment complexity in BE after radiofrequency ablation
A novel risk model predicted treatment complexity among patients with Barrett’s esophagus following initial radiofrequency ablation treatment, according to research published in Clinical Gastroenterology and Hepatology.